Tan Susanna, Ayutyanont Napatkamon, Bhattarai Bikash, Movahedi Zohreh, Jayaram Lakshmi, Gish Robert, Nadir Abdul
Maricopa Medical Center, Phoenix, Arizona, USA.
University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.
BMJ Open Gastroenterol. 2017 Sep 25;4(1):e000158. doi: 10.1136/bmjgast-2017-000158. eCollection 2017.
To assess whether aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (AP) levels can predict the diagnosis of primary biliary cholangitis (PBC) or any other diagnoses and whether PBC occurs either simultaneously or independently of other liver diseases among antimitochondrial antibody (AMA)-positive patients.
Demographic and clinical variables were assessed in 90 AMA-positive patients with and without liver biopsies. These patients were further categorised as having a diagnosis of PBC, overlap syndrome or 'not established with a diagnosis of PBC'. Receiver operating characteristic curves were constructed to determine the thresholds of liver enzymes that predict these three diagnoses.
The 48 patients with liver biopsies were more frequently female and had significantly higher AP levels compared with the non-liver biopsy group. Based on liver biopsy findings, 12, 12 and 22 patients were assigned a diagnosis of PBC, overlap syndrome with autoimmune hepatitis and PBC and 'not established diagnosis of PBC', respectively. Seven of 12 patients classified as PBC had AP level of ˂200 IU. AST, ALT and AP levels were significant predictors of a diagnosis of overlap syndrome compared with the rest of the patients; however, these tests were not discriminatory between diagnoses of PBC and 'not established with PBC'. Findings of fatty liver and bile duct injury on liver biopsies were not significantly associated with any liver test pattern.
As the liver test pattern did not correlate with the liver biopsy findings of PBC or other non-PBC diagnoses in AMA-positive patients at risk for other disease, a liver biopsy and/or non-invasive liver assessment along with serum liver tests should be interpreted to complete liver evaluation.
评估天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和碱性磷酸酶(AP)水平能否预测原发性胆汁性胆管炎(PBC)的诊断或其他任何诊断,以及在抗线粒体抗体(AMA)阳性患者中,PBC是与其他肝病同时发生还是独立发生。
对90例AMA阳性患者进行了人口统计学和临床变量评估,这些患者有的进行了肝活检,有的未进行肝活检。这些患者进一步分为诊断为PBC、重叠综合征或“未确诊为PBC”。构建受试者工作特征曲线以确定预测这三种诊断的肝酶阈值。
与未进行肝活检的组相比,48例进行了肝活检的患者女性更为常见,AP水平显著更高。根据肝活检结果,分别有12例、12例和22例患者被诊断为PBC、重叠综合征合并自身免疫性肝炎和PBC以及“未确诊为PBC”。在分类为PBC的12例患者中,有7例AP水平<200 IU。与其他患者相比,AST、ALT和AP水平是重叠综合征诊断的确切预测指标;然而,这些检测在PBC诊断和“未确诊为PBC”之间没有鉴别意义。肝活检中脂肪肝和胆管损伤的结果与任何肝检测模式均无显著相关性。
由于在有其他疾病风险的AMA阳性患者中,肝检测模式与PBC或其他非PBC诊断的肝活检结果不相关,因此应结合肝活检和/或非侵入性肝评估以及血清肝检测来完成肝脏评估。